About Us

AMPEL BioSolutions

Culture is the organization’s immune system.
—Michael Watkins

Mission

AMPEL BioSolutions was founded to bring personalized precision medicine to patients, especially those with autoimmune and inflammatory diseases.

Our Why

Autoimmune and inflammatory disease patients are not receiving the precise, personalized evaluation and treatment that they deserve. The immune system of autoimmune patients is complex, dynamic and not accurately assessed by current technologies.

The AMPEL team brings their expertise in basic and translational research, clinical trial design, and bioinformatics together in a new way to develop scalable systems using AI and deep machine learning to improve patient outcomes. To give patients and their doctors the tools and information necessary to make decisions based on that individual’s genomic profile — what we term their Genomic Fingerprint.

Your Genes have a lot to tell you.

We are your translator

AMPEL BioSolutions identifies your Genomic Fingerprint®️
providing personalized precision medicine.

In 2022, AMPEL expects to commercialize its first product, a CLIA-certified blood test for patients/physicians, LuGENE®, that assesses disease state/flares and drug options. AMPEL’s technology covers >95% of all known genes and is disease agnostic so there is capacity to expand reporting of results into new disease indications without developing a new test. AMPEL’s exclusive curated database of >10,000 autoimmune patient gene expression profiles and 5,000 healthy individuals with rich clinical information is the world’s largest and fuels machine learning predictions based on evidence.

Your Genes have a lot to tell you.

We are your translator

AMPEL BioSolutions identifies your Genomic Fingerprint®️
providing personalized precision medicine.

In 2022, AMPEL expects to commercialize its first product, a CLIA-certified blood test for patients/physicians, LuGENE®, that assesses disease state/flares and drug options. AMPEL’s technology covers >95% of all known genes and is disease agnostic so there is capacity to expand reporting of results into new disease indications without developing a new test. AMPEL’s exclusive curated database of >10,000 autoimmune patient gene expression profiles and 5,000 healthy individuals with rich clinical information is the world’s largest and fuels machine learning predictions based on evidence.

Expertise

RNA analytics, Bioinformatics and Machine Learning/AI

Disease Areas

Systemic Lupus Erythematosus, Psoriasis, Scleroderma, Atopic Dermatitis, Lupus Nephritis, Fibromyalgia, Cardiovascular, Sjogren’s Syndrome, Lung Cancer, SARS-Cov2

Why AMPEL

Reproducible

LDT for providers

Scalable

From Pharma to mainstream adoption by providers

Translatable

Digital Health Tool

Clinical Decision Support

Precise real-time evaluation of immune status

Clinical Care Pathway

Evidence-based disease management through RNA analytics

Who We Work With

AMPEL seeks relationships with Pharmaceutical and Precision medicine companies:

• Co-Develop RNA analytic tests in desired disease areas
• License with field of use for specific conditions
• Use of AGP®, Bioinformatic tools and ML/AI Algorithms

Company Milestones

Patents

AMPEL’s technology is covered by 22+ provisional and 5 non-provisional patents filed by Wilson Sonsini Goodrich and Rosati in Immunology, inflammation, Infectious disease and oncology.

Database

Exclusive curated database of >15,000 Autoimmune and normal patient gene expression profiles with rich clinical information.

World’s Largest for Lupus.

Validation and Expansion

Approach validated by KOLs and 15+ pharma/biotech clients.
Advisors for LDT Reimbursement in place.

Launch and Growth

2022 Planned Activities

  • New Product Launch
  • Establish strategic partnerships
  • Five other autoimmunity products to be launched by 2024

Peer-Reviewed Articles

Pin It on Pinterest